LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial
Open accessThe DOI matches its Crossref record.
Overview
CoChat Summary
TL;DR
In the phase 3 KRYSTAL-10 trial, second-line adagrasib plus cetuximab did not significantly improve progression-free survival or overall survival versus chemotherapy in patients with KRAS G12C-mutated metastatic colorectal cancer, though objective response rate was substantially higher with the targeted combination. The authors conclude the regimen showed antitumor activity with manageable safety as a chemotherapy-free option.
Key findings
- Median PFS by blinded independent central review was 7.5 months (95% CI 6.3–9.2) with adagrasib + cetuximab vs 8.1 months (95% CI 7.3–9.2) with chemotherapy (HR 0.89, 95% CI 0.71–1.13; P = 0.32).
- At a minimum follow-up of 26.4 months, median OS was 21.6 months (95% CI 18.4–25.5) vs 21.7 months (95% CI 18.0–24.8) (HR 0.83, 95% CI 0.67–1.03; P = 0.09). The study did not achieve statistical significance for either dual primary endpoint.
- ORR was 47% (108/231; 95% CI 40–53) with adagrasib + cetuximab vs 16% (36/230; 95% CI 11–21) with chemotherapy, with higher complete response rates (7% vs <1%).
- Safety: any-grade/grade 3–5 treatment-related TEAEs occurred in 225 (98%)/105 (46%) of 230 patients on adagrasib + cetuximab vs 198 (96%)/113 (55%) of 206 on chemotherapy; serious treatment-related TEAEs in 9% vs 12%; discontinuation due to treatment-related TEAEs in 3% vs 2%. No new safety signals were observed.
Methods
- Global, open-label, randomized phase 3 trial (KRYSTAL-10; NCT04793958) in patients with KRAS G12C-mutated metastatic CRC who progressed on first-line fluoropyrimidine-based doublet chemotherapy with oxaliplatin or irinotecan.
- 461 patients randomized 1:1 to adagrasib 600 mg twice daily plus cetuximab 500 mg/m² every 2 weeks (n = 231) or chemotherapy (FOLFIRI or mFOLFOX6, ± VEGF/VEGFR inhibitors; n = 230).
- Dual primary endpoints: PFS by blinded independent central review (database lock 15 Apr 2025) and OS (database lock 23 Feb 2026). Key secondary endpoints included ORR (DBL 15 Apr 2025) and safety.
Limitations
- The paper states no formal limitations; it notes only that "further analysis will be presented," so subgroup, biomarker, and post-progression/crossover data are not available in this report.
- Evident from the text: this is a conference abstract (LBA1) with limited methodological detail — no information on randomization stratification, statistical design assumptions, or handling of crossover, which matters given the numerically favorable OS hazard ratio that did not reach significance.
- Evident from the text: the safety comparison uses different denominators (230 treated with adagrasib + cetuximab vs 206 with chemotherapy), and the abstract reports no quality-of-life or patient-reported outcomes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 0 Not checked · 13 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The study did not achieve statistical significance for its primary endpoints.”
§ LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Any-grade/grade 3-5 treatmentrelated TEAEs 225 (98)/105 (46) 198 (96)/113 (55)”
§ LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ORR was numerically higher with Ada + Cetux vs chemo (47% vs 16%; Table)”
- Also stated in: § Abstract · plain
“ORR, a,b n (%); 95% CI 108 (47); 40-53 36 (16); 11-21”
§ LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median PFS per BICR was 7.5 mo with Ada + Cetux vs 8.1 mo with chemo (HR 0.89 [95% CI 0.71-1.13];P = 0.32; Table).”
- Also stated in: § Abstract · plain
“Median PFS (95% CI), a,b mo 7.5 (6.3-9.2) 8.1 (7.3-9.2) HR (95% CI) 0.89 (0.71-1.13);P = 0.32”
§ LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Any-grade/grade 3-5 treatmentrelated TEAEs 225 (98)/105 (46) 198 (96)/113 (55)”
§ LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
6 more claims
Create a free account to see all 13 claims and every source verdict.
- Probably not a substantial claim. 1
- It may state two separate claims as one. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial > Additional information
“Among pts who received <6c of mFOLFOX6, 3y-DFS was similar in the atezocontaining arm (80.0%n=41) vs mFOLFOX6 alone (79.9% n=43) [aHR 0.85 (95% CI 0.32-2.29].However, pts who received ≥6c of mFOLFOX6 had a 3y-DFS that was superior when combined with atezo (88.2% n=279) vs mFOLFOX6 alone (79.1% n=254)”
§ LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial > Additional information
“Among pts who received <7c of mFOL-FOX6, 3y-DFS was similar with atezo (78.2% n=46) or without it (78.7%n=60).Among pts who received ≥7c, 3y-DFS was superior when combined with atezo (88.5% n=270) vs not (79.4% n=235)”
Citations
Cites
Still being checked.
Research works printed but not linked: 2
- C.H. Lieu: Financial In- terests, Institutional, Invited Speaker, Research Funding: Genentech. E.M. O'Reilly: Financial In- terests, Personal, Advisory Board, Travel reimbursement only: BioNTech, Pfizer; Financial Interests, Personal, Advisory Board, +Spouse: Ipsen; Financial Interests, Personal, Advisory Board: Merck, AstraZeneca, Novartis, Astellas, BMS, Exelixis, Agenus, Moma Therapeutics; Financial Interests, Personal, Advisory Board, Spouse: Genentech/Roche, Eisai, Autem; Financial Interests, Personal, Other, Data and Safety Monitoring Board: Ability Pharma; Financial Interests, Personal, Invited Speaker: Research To Practice; Financial Interests, Institutional, Invited Speaker: Genentech/Roche, Arcus, Elicio, AstraZeneca, Pertzye, Tango Therapeutics; Financial Interests, Personal and Institu- tional, Invited Speaker: BioNTech; Financial Interests, Institutional, Research Grant: Parker Institute; Financial Interests, Personal and Institutional, Invited Speaker, Consulting personal -uncompen- sated: Revolution Medicine; Financial Interests, Personal and Institutional, Invited Speaker, Clinical trial Advisory Board: Agenus; Non-Financial Interests, Other, Scientific and Medical Advisory Board Uncompensated: Pancreas Cancer Action Network; Non-Financial Interests, Member of Board of Directors, Vice-Chair Uncompensated: National Pancreas Foundation; Non-Financial Interests, Other, Scientific advisory Board Uncompensated: Hirshberg Foundation; Other, Editor: American Society of Clinical Oncology, American Association of Cancer Research (AACR); Other, PI SPORE Grant to MSK (institution): NCI/NIH; Other, Investigator on grant (to institution): Break- ThroughCancer.
- Financial Interests, Personal, Advisory Board, Advisory Board participations and Honoraria for Presentations: Takeda; Financial Interests, Personal, Invited Speaker, CME Provider. 2025 institu- tional only: Art Tempi media; Financial Interests, Personal, Advisory Board, CME Provider, App Producer: Onkowissen; Financial Interests, Personal, Other, Roles as Associate Editor for ESMO Open (until end of 2025) and Ann Oncol (ongoing): Elsevier; Financial Interests, Personal, Other, Role as Associate Editor Clin Colorect Cancer (until end 2025): Elsevier; Non-Financial Interests, Project Lead, non-compensated Scientific Advisory Board member: OncoLytics; Non-Financial In- terests, Advisory Role, non-compensated Scientific Advisory Board member: Phanes Therapeutics Inc.; Non-Financial Interests, Leadership Role, GI Group Steering Committee: EORTC; Non-Financial Interests, Leadership Role, Steering Committee Member: AIO (German Cancer Society); Non- Financial Interests, Member: ASCO, ESO, DGHO. F.A. Sinicrope: Financial Interests, Personal, Invited Speaker: Hoffman La Roche; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Role: Guardant Health; Other, Institutional, Royalties, Co-inventor, patent: Roche Ventana Medical Systems. All other authors have declared no conflicts of interest. https://doi.org/10.1016/j.annonc.2026.05.005 · DOI
Cited by
KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions
Sagawa, T., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01547-2
(2026) · Oncology Times · doi:10.1097/01.cot.0000000000000532
Tang, K., Xie, Y., Khalifa, S. A. M., El-Seedi, H. R., & Coghi, P. S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119493
Eslinger, C. R., Ahn, D., Jin, Z., Strickler, J. H., & Bekaii-Saab, T. (2026) · Future Oncology · doi:10.1080/14796694.2026.2758043
Metadata
- Authors
- Tabernero, J., Kopetz, S., Lee, J., Corcoran, R. B., Hecht, J. R., Shen, L., Lonardi, S., Chen, Y., Fuang, H. G., Chen, Z., Saunders, M. P., Paulson, A. S., Spanakis, E., Ogburn, K. D., Ahmad, H. A., & Yaeger, R.
- Affiliations
- Vall d'Hebron Institute of Oncology (ES)
- The University of Texas MD Anderson Cancer Center (US)
- Samsung Medical Center (KR)
- Massachusetts General Hospital (US)
- University of California, Los Angeles (US)
- Peking University Cancer Hospital (CN)
- Istituto Oncologico Veneto (IT)
- Fujian Provincial Cancer Hospital (CN)
- University Kebangsaan Malaysia Medical Centre (MY)
- Fudan University Shanghai Cancer Center (CN)
- The Christie Hospital (GB)
- Bristol-Myers Squibb (Switzerland) (CH)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2026-07
- Volume
- 37
- Pages
- S1-S2
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W7168730212
- Cited by
- 4
- References
- 0
- Citations by year
- 2026: 4
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Roche
- Sanofi
- European Association for Cancer Research
- American Society of Clinical Oncology
- Memorial Sloan-Kettering Cancer Center
- Baylor University
- University of Pittsburgh
- Taiho Pharmaceutical
- Mirati Therapeutics
- BeiGene
- Cancer Research UK
- Fundación Científica Asociación Española Contra el Cáncer
- Universidad de Navarra
- Sociedad Española de Oncología Médica
- Servier
- Novartis Farmacéutica
- Deutschen Konsortium für Translationale Krebsforschung
- INCLIVA Instituto de Investigación Sanitaria
- Genentech
- Chugai Pharmaceutical
- Cancer Center, University of Colorado
- Baylor University Medical Center
- Ignyta
- HORIZON EUROPE Framework Programme
- National Cancer Institute
- Cilag
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- adagrasib, cetuximab, KRAS G12C mutation, metastatic colorectal cancer, second-line therapy, KRAS inhibitors, chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial. https://app.cochat.ai/papers/10.1016/j.annonc.2026.06.005
- The paper
- Tabernero, J., Kopetz, S., Lee, J., Corcoran, R. B., Hecht, J. R., Shen, L., Lonardi, S., Chen, Y., Fuang, H. G., Chen, Z., Saunders, M. P., Paulson, A. S., Spanakis, E., Ogburn, K. D., Ahmad, H. A., & Yaeger, R. (2026). LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial. Annals of Oncology. https://doi.org/10.1016/j.annonc.2026.06.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.